Use of gonadotrophin-releasing hormone agonists to trigger ovulation

References

• Damewood MD, Shen W, Zacur HZ, Schlaff WD, Rock JA, Wallach EE. Disappearance of exogenously administered human chorionic gonadotropin. Fertility and Sterility 1989; 52: 398–400
   PubMed Web of Science ®Google Scholar
• Emperaire JC, Ruffie A. Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Human Reproduction 1991; 6: 506–510
   PubMed Web of Science ®Google Scholar
• European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 2001; 16: 644–651
   PubMed Web of Science ®Google Scholar
• European Orgalutran Study Group, Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomised, multicentre trial. Human Reproduction 2000; 15: 1490–1498
   PubMedGoogle Scholar
• Fauser BC, Devroey P, Yen SS, Gosden R, Crowley WF, Jr, Baird DT, Bouchard P. Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Human Reproduction 1999; 14: 2681–2686
   PubMed Web of Science ®Google Scholar
• Felberbaum RE, Reissmann T, Kupker W, Bauer O, Al Hasani S, Diedrich C, Diedrich K. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. European Journal of Obstetrics, Gynaecology and Reproductive Biology 1995; 61: 151–155
   PubMed Web of Science ®Google Scholar
• Forman R, Fries N, Testart J, Belaisch J, Hazout A, Frydman R. Evidence of an adverse effect of elevated serum estradiol concentrations on embryo implantation. Fertility and Sterility 1988; 49: 118–122
   PubMed Web of Science ®Google Scholar
• Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. Journal of Clinical Endocrinology and Metabolism 1990; 71: 918–922
   PubMed Web of Science ®Google Scholar
• Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: a re-evaluation. Journal of Clinical Endocrinology and Metabolism 1983; 57: 792–796
   PubMed Web of Science ®Google Scholar
• Imoedemhe DA, Chan RC, Sigue RB, Pacpaco EL, Olazo AB. A new approach to the management of patients at risk of ovarian hyperstimulation in an in vitro fertilization program. Human Reproduction 1991; 6: 1088–1091
   PubMed Web of Science ®Google Scholar
• Imthurn B, Piazzi A, Loumaye E. Recombinant human luteinizing hormone to mimic mid-cycle LH surge. Lancet 1996; 348: 332–333
   PubMedGoogle Scholar
• Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes J. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertility and Sterility 1991; 56: 213–220
   PubMed Web of Science ®Google Scholar
• Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Human Reproduction 2000; 15: 1965–1968
   PubMed Web of Science ®Google Scholar
• Kol S, Lewit N, Itskovitz-Eldor J. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications. Human Reproduction 1996; 11: 1143–1144
   PubMed Web of Science ®Google Scholar
• Lanzone A, Fulghesu AM, Villa P, Guida C, Guido M, Nicoletti MC. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovary disease gonadotropin hyperstimulated cycles. Fertility and Sterility 1994; 62: 35–41
   PubMedGoogle Scholar
• Mannaerts BM, Geurts TBP, Odink J. A randomised three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Human Reproduction 1998; 13: 1461–1466
   PubMed Web of Science ®Google Scholar
• Nakano R, Mizuno T, Kotsuji F, Katayama K, Wshio M, Tojo S. ‘Triggering˚s of ovulation after infusion of synthetic luteinizing hormone releasing factor (LRF). Acta Obstetrics and Gynaecology Scandinavia 1973; 52: 269–272
   PubMed Web of Science ®Google Scholar
• North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 2001; 75: 38–45
   PubMedGoogle Scholar
• Oberye JJ, Mannaerts BM, Kleijn HJ, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertility and Sterility 1999a; 72: 1001–1005
   PubMed Web of Science ®Google Scholar
• Oberye JJ, Mannaerts BM, Huisman JA, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertility and Sterility 1999b; 72: 1006–1012
   PubMed Web of Science ®Google Scholar
• Olivennes F. Induction of final oocyte maturation by a single dose of GnRH agonist after ganirelix treatment. Gynecological Endocrinology 2001; 15(Supplement 1), Abstract 12
   Google Scholar
• Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertility and Sterility 1996; 66: 151–153
   PubMed Web of Science ®Google Scholar
• Porchet HC, Le Cotonnec JY, Neuteboom B, Canali S, Zanolo G. Pharmocokinetics of recombinant human luteinizing hormone, intramuscular and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinizing hormone. Journal of Clinical Endocrinology and Metabolism 1995; 80: 667–673
   PubMed Web of Science ®Google Scholar
• Revel A, Casper RF. The use of LHRH agonists to induce ovulation. Infertility and Reproductive Medicine Clinics of North America 2001; 12: 105–118
   Google Scholar
• Romeu A, Monzo A, Peiro T, Diez E, Peinado JA, Quintero LA. Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: a comparison of 761 cycles. Journal of Assisted Reproduction and Genetics 1997; 14: 518–524
   Google Scholar
• Segal S, Casper RF. Gonadotropin-releasing hormone agonist versus chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. Fertility and Sterility 1992; 57: 1254–1258
   PubMed Web of Science ®Google Scholar
• Shoham Z, Schachter M, Loumaye E, Weissman A, MacNamee M, Insler V. The luteinizing hormone surge — the final stage in ovulation induction: modern aspects of ovulation triggering. Fertility and Sterility 1995; 64: 237–251
   PubMed Web of Science ®Google Scholar
• Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ. Ovarian response in women to recombinant follicle-stimulating hormone and luteinizing hormone: a role for LH in the final stages of follicle maturation. Journal of Clinical Endocrinology and Metabolism 1999; 84: 228–232
   PubMed Web of Science ®Google Scholar
• Van de Meer S, Gerris J, Joosten M, Tas B. Triggering of ovulation using a gonadotrophin-releasing hormone agonist does not prevent ovarian hyperstimulation syndrome. Human Reproduction 1993; 8: 1628–1631
   Google Scholar
• Whelan JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertility and Sterility 2000; 73: 883–896
   PubMed Web of Science ®Google Scholar